Latest Tumor suppressor genes Stories
Scientists at the Princess Margaret Cancer Centre have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients, a finding that could aid in delivering tailored, personalized cancer medicine based on an individual's genetics.
Genetic mutations aren’t the only thing that can keep a protein called PTEN from doing its tumor-suppressing job.
It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumors are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2.
Fulgent Therapeutics, a CLIA Certified Laboratory, announces today the inclusion of BRCA1 and BRCA2 analysis into its Hereditary Cancer Panel. Temple City, CA
Plaintiffs, including the American Civil Liberties Union, Association for Molecular Pathology, and American Society for Clinical Pathology, win long-fought case against Myriad Genetics, Association
A Salt Lake City, Utah-based genetics firm has lost a battle in court to keep a patent on naturally-occurring human genes.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.